Invion Advances Non-Melanoma Skin Cancer Trial with Successful Initial Dosing

An announcement from Invion ( (AU:IVX) ) is now available.

Invion Limited has successfully dosed the first six patients in its Phase I/II trial for non-melanoma skin cancer (NMSC) using its topical drug INV043. This milestone initiates a safety review by the Safety Review Committee, which will assess the need for adjustments in the trial’s next stage. The trial, which evaluates the safety and efficacy of INV043, aims to provide an effective alternative to surgery, potentially reducing scarring and pain. The global market for NMSC treatment is projected to reach $21.1 billion by 2032, highlighting the significance of Invion’s advancements in this field.

More about Invion

Invion is a life-science company specializing in the research and development of Photosoft technology for treating various cancers, atherosclerosis, and infectious diseases. It holds exclusive licensing rights in Australia, New Zealand, and parts of Asia Pacific for cancer indications, and in Asia and Oceania for atherosclerosis and infectious diseases. Invion is listed on the ASX and its research is funded by RMW Cho Group Limited.

YTD Price Performance: -28.00%

Average Trading Volume: 1,000

Technical Sentiment Signal: Buy

Current Market Cap: $4.97M

For a thorough assessment of IVX stock, go to TipRanks’ Stock Analysis page.